Republic Republic Republic
  • Log in
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
Primary market Live deals Secondary market Buy and sell Republic Note Own a piece of Republic's upside Investor Network Membership Receive exclusive discounts and benefits
Republic Venture Opportunities for accredited investors
Republic Capital Multi-stage venture firm Republic Digital Crypto hedge fund
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets Sharedrops Gift equity as a reward
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets Tokenization Deploy your assets on-chain Asset management Explore digital asset funds
Republic Capital In-house Venture Capital fund Broker dealer Regulated capital services
Log in Sign up

Republic Republic Republic
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
  • US
  • Log in
  • Sign up
All investors
Primary market Live deals Secondary market Buy and sell Republic Note Own a piece of Republic's upside Investor Network Membership Receive exclusive discounts and benefits
Accredited only
Republic Venture Opportunities for accredited investors
Institutional
Republic Capital Multi-stage venture firm Republic Digital Crypto hedge fund
More
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Spotlight deal
ASM Capital Whiskey Fund
ASM Capital Whiskey Fund
Funding the emergence of American Single Malt
Growth capital solutions
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets
Sharedrops Gift equity as a reward
Web3 services
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets Tokenization Deploy your assets on-chain Asset management Explore digital asset funds
Institutional services
Republic Capital In-house Venture Capital fund
Broker dealer Regulated capital services

Pollie isn't accepting new investments

Explore new investment opportunities:

View companies raising now
Logo of Pollie

Pollie

The hub for women affected by complex chronic conditions — starting with PCOS
B2C Women Founders Wellbeing & Longevity Healthtech SaaS
Facebook Telegram Twitter LinkedIn
Featured image of Pollie
Pollie has withdrawn its campaign
All investments have
been refunded.

Check out other startups
Invest in Pollie
Campaign closed
Pitch Discussion 7 Updates Reviews 3
Invest Invest in Pollie
Facebook Telegram Twitter LinkedIn
Problem Solution Product Traction Customers Biz. model Market Competition Vision and strategy Impact Funding Founders Summary
About Team Press FAQ Risks Discussion

Documents

Republic (OpenDeal Portal LLC, CRD #283874) is hosting this Reg CF securities offering by Pollie, Inc.. View the official SEC filing and all updates:
Official SEC Logo Form C SEC.gov
Company documents
Pollie Crowd SAFE Pollie Form C.pdf
Loading

Hear from some of the 0 people reserved or invested in Pollie


Show more

Highlights


  • PCOS impacts 10% of females (7 million people in U.S.)
  • PCOS costs $2k-13k/yr to manage, harms QoL, and status quo care is failing
  • Pollie's app provides personalized, evidence-based, OBGYN-backed PCOS care
  • 83% of Pollie members feel better after 2 months
  • Long-term: One-stop-shop for 30% of females with a chronic condition
  • Participated in Bayer's G4A accelerator (largest investor)

Problem


7 million people in the United States suffer from polycystic ovarian syndrome (PCOS)

Status quo PCOS care fails patients in many ways.


PCOS impacts 10% of females with the following symptoms:

  • Menstruation: Irregular or absent menstrual cycles, painful periods, heavy bleeding, infertility
  • Metabolism: Trouble losing weight, insulin resistance 
  • Skin / hair: Acne, hair loss, hirsutism, skin discoloration 
  • Mood: Anxiety, depression, insomnia

While best known for its fertility implications, PCOS is a whole-body condition that leads to serious complications if left unmanaged. But that status quo treats PCOS symptoms discretely and reactively, and the patient experience is full of frustrations and gaps. 

Solution


Pollie is redefining  PCOS care with our personalized and sustainable digital program

And PCOS is just the beginning: our existing program used as a playbook for expanding into other hormone, autoimmune, and digestive disorders that impact women.


Product


Pollie's PCOS iOS mobile app:
What’s included?

Our approach helps pinpoint the catalyst of symptoms in a convenient, efficient, and personalized way.

Traction


Over 80% of our members see an improvement in symptoms in just 2 months

With nearly entirely organic marketing and almost no paid advertising, we have achieved the following:

  • Nearly 1,000 app downloads 
  • Over 95% satisfaction with Pollie care team visits
  • 90% of Pollie members would recommend our app to a friend, colleague, or family member 
  • 96% weekly active users 
  • 45% daily active user / monthly active user ratio

Customers


Pollie's target members are menstruating people with a PCOS diagnosis

90% of our members are finding us
through social media, and 10% through search. 


Our members come to us because they are not satisfied with the current quality or quantity of care they are receiving and are looking for additional support. 

Our members currently live all across the United States and Canada. Most of our members are 25 – 40 years old and are either are young professionals or actively trying to conceive. 

Positive early feedback validates a need for Pollie's app. Here's what our members are saying:

Business model


Today  we monetize with an out-of-pocket subscription

In the future, we will contract with
payers to expand access to quality PCOS care.


Similar to other chronic disease management startups, we are working toward a B2B2C model to help payers (commercial health insurance, self-insured employers, and Medicaid plans) lower care costs for their PCOS patients.

One of the major milestones of our seed round will be to run an interventional study.

Pollie's approach is built on abundant peer-reviewed research that demonstrates our interventions are effective. This, combined with our early outcomes metrics, signal that this study will demonstrate a significant improvement in PCOS health and cost outcomes. This will put us in a strong position to sell to payers.

Market


PCOS is a significant opportunity; our growth markets are even larger

PCOS and related conditions are costing individuals and our healthcare system billions of dollars because they are being treated reactively rather than proactively.


Annual U.S. spend on PCOS and similar conditions

Now is the time to disrupt this space. Media sources like The New York Times, HuffPost, Vogue, The Guardian, The Today Show, and countless women's health publications have been spotlighting PCOS. Celebrities with significant influence in our target demographic (e.g., Victoria Beckham, Keke Palmer, Romee Strijd, and more) have also shared their struggles with PCOS, as have a growing number of microinfluencers. Tip: Check out #pcos hashtags Instagram and Tiktok!

The market is showing it is ready for better PCOS solutions.

Competition


A one-stop-shop is needed for female complex chronic conditions

Larger female health companies are not meeting this need, and an uptick of competitive offerings validates the demand for a solution like Pollie.



—
We differentiate with our behavior change focus,
partner network approach, and programmatic model:
—


Vision and strategy


Our vision is to redefine care for female complex chronic conditions

PCOS is just the beginning.

PCOS is a massive market, and there is high demand for out-of-pocket consumer health services. But to have the most impact, we will expand into adjacent conditions and also work with healthcare incumbents. 

—

We are testing monetization starting with a DtC subscription, and are working with a large TAM

—

Potential exits

  • Acquisition by incumbent healthcare player (e.g., fertility clinic chain) to better optimize their results 
  • Acquisition by larger health tech player in women's health, chronic disease management, or general telehealth who is looking to expand their offerings 
  • IPO as go-to source for all complex chronic conditions for menstruating people 

Impact


Pollie's mission is to make high quality PCOS
care accessible

to all menstruating people, regardless of their socioeconomic status, race, or gender. 

Female health is underserved, under-researched, and under-funded. This dynamic is even more extreme for PCOS (and other complex chronic conditions that impact menstruating people) than other markets within female health.  

PCOS is a public health issue: not only does it impact 10% of the menstruating population, but it also disproportionately impacts minority racial groups and people in lower income tiers.

That is why eventual insurance reimbursement (commercial plans, self-insured employers, and Medicaid) is such an important priority on our roadmap. 

Funding


Backed by angels & VCs

We have raised nearly $900k total thus far from our angel and pre-seed rounds from a variety of institutional, corporate, and angel investors:

—

We are raising a $3 million seed round to give us 18+ months of runway to validate our PCOS app for B2B2C channels.


Founders


Jane Sagui & Sabrina Mason

Our founders Jane and Sabrina met nearly a decade ago while studying abroad in college. The two were randomly assigned as roommates in a single-room quad and were fast friends.

Summary


Join us

Today's typical PCOS patient experience is inadequate to properly manage the condition. For a condition that leads to such debilitating symptoms and costly future health risks, inadequate is unacceptable. 

Research and our early outcomes show that Pollie's approach far outperforms status quo PCOS care both in health outcomes and patient satisfaction. We are eager to continue not just improving, but redefining, PCOS care alongside partners who are just as excited by our vision as we are. 

- Jane & Sabrina

Deal terms


Valuation cap

$15,000,000

The maximum valuation at which your investment converts into equity shares or cash.
Learn more

Minimum investment

$100

The smallest investment amount that Pollie is accepting.
Learn more

Maximum investment

$123,500

The largest investment amount that Pollie is accepting.
Learn more

Funding goal

$1M

Pollie must achieve its minimum goal of $25K before the deadline. The maximum amount the offering can raise is $1M.
Learn more

Deadline
Pollie needs to reach their minimum funding goal before the deadline ( ). If they don’t, all investments will be refunded.
Learn more
Type of security

Crowd SAFE

A SAFE allows an investor to make a cash investment in a company, with rights to receive certain company stock at a later date, in connection with a specific event. · Learn more

Nominee Lead

Chief Executive Officer of the Company (currently Jane Sagui)

Will direct the Nominee on certain matters like voting, amendments and conversions affecting the security.
Learn more

How it works

Documents

Republic (OpenDeal Portal LLC, CRD #283874) is hosting this Reg CF securities offering by Pollie, Inc.. View the official SEC filing and all updates:
Official SEC Logo Form C SEC.gov
Company documents
Pollie Crowd SAFE Pollie Form C.pdf

Bonus perks

In addition to your Crowd SAFE, you'll receive perks for investing in Pollie.
Invest
$1,000
Receive
  • Sponsor 1 person through 3 months of Pollie's PCOS Program
Invest
$5,000
Receive
  • Sponsor 3 people through 3 months of Pollie's PCOS Program
Invest
$10,000
Receive
  • Sponsor 4 people through 3 months of Pollie's PCOS Program
  • Free Baseline or Essentials Pollie lab package for yourself or a loved one
Invest
$25,000
Receive
  • Sponsor 6 people through 3 months of Pollie's PCOS Program
  • Free Baseline, Essentials, or Advanced Pollie lab package for yourself or a loved one
Invest
$50,000
Receive
  • Sponsor 10 people through 3 months of Pollie's PCOS Program
  • Free Baseline, Essentials, or Advanced Pollie lab package for yourself or a loved one
  • Advisory role (if desired) relating to your personal and / or professional experience

About Pollie

Legal Name
Pollie, Inc.
Founded
Apr 2020
Form
Delaware Corporation
Employees
4
Website
pollie.co
Social Media
Headquarters
Google Map location of of Pollie
1600 North Broadway 1600 , Denver, CO
Headquarters
1600 North Broadway, 1600, Denver, CO, United States 80202

Pollie Team
Everyone helping build Pollie, not limited to employees

Profile picture of Jane Sagui
Jane Sagui
Co-founder & CEO
Jane has been passionate about women's health, and more specifically hormonal health, since being diagnosed with PCOS nearly a decade ago. She previously focused on digital health companies as a management consultant (PwC) and VC (NGP Capital).
Profile picture of Sabrina Mason
Sabrina Mason
Co-founder & COO
Sabrina has a public health background. She has experience working with providers (Boston Children's) and health tech companies (athenahealth, Tempus) where she held a variety of operational and product roles.
Profile picture of Sam Ennis
Sam Ennis
CTO
Sam is a software architect who has spent a decade building human-services software for millions of users, ranging from statewide Covid relief disbursement to cancer therapy management. He loves journalism, social science, and amateur entomology.
Profile picture of Janice Yiu
Janice Yiu
Content & Community Lead
Janice is a certified Health and Nutrition Coach with a background in marketing within the health and wellness space. She focuses on brand marketing, copywriting, and content creation.
Profile picture of Dr. Melanie Green, PhD
Dr. Melanie Green, PhD
Medical & Research Advisor
Dr. Melanie Green is one of the country’s leading pediatric endocrinologists and researchers specializing in PCOS in adolescence. She is founder and Director of the Multi-Disciplinary PCOS Clinic at Children’s Hospital Colorado.
Profile picture of Dr. Gina Merchant, PhD
Dr. Gina Merchant, PhD
Behavior Science Advisor
Dr. Merchant is a behavior scientist who has experience in chronic care management platforms, remote monitoring, wearables, and health coaching. Her expertise is in cardio-metabolic health, intervention design, and user engagement.
Profile picture of Dr. Avi Tsur, PhD, OBGYN
Dr. Avi Tsur, PhD, OBGYN
Medical & Research Advisor
Dr. Avi Tsur is Founder and Director of the Sheba Women’s Health Innovation Center in Israel. He completed his fellowship at Stanford and has done a wide range of women's health research.
Profile picture of Dr. Pooja Mahtani, PharmD, CNS
Dr. Pooja Mahtani, PharmD, CNS
Medical Advisor
Dr. Mahtani is a functional nutritionist and previous pharmacist whose current work focuses on helping women with PCOS and other hormone conditions find the root cause of their symptoms.
Profile picture of Rebecca Thieneman, MS, RDN, NBC-HWC
Rebecca Thieneman, MS, RDN, NBC-HWC
Medical & Care Team Advisor
Rebecca is a functional practitioner who has scaled coached teams at other digital health companies. Under her oversight, she took Omada's team from 10 to 100+ coaches.
Profile picture of Dr. Saru Bala, ND
Dr. Saru Bala, ND
Medical Advisor
Profile picture of Valerie Agyeman, RD
Valerie Agyeman, RD
Medical Advisor
Profile picture of Dr. Morgan West, DO, OBGYN
Dr. Morgan West, DO, OBGYN
Medical Advisor
9 more team members
Jane Sagui
Co-founder & CEO
Sabrina Mason
Co-founder & COO
Sam Ennis
CTO
Janice Yiu
Content & Community Lead
Dr. Melanie Green, PhD
Medical & Research Advisor
Dr. Gina Merchant, PhD
Behavior Science Advisor
Dr. Avi Tsur, PhD, OBGYN
Medical & Research Advisor
Dr. Pooja Mahtani, PharmD, CNS
Medical Advisor
Dr. Saru Bala, ND
Medical Advisor
Valerie Agyeman, RD
Medical Advisor
Rebecca Thieneman, MS, RDN, NBC-HWC
Medical & Care Team Advisor
Dr. Morgan West, DO, OBGYN
Medical Advisor

Press

Nine digital health pioneers to join Bayer's G4A program
MobiHealthNews
·
Nov 30, 2021

A total of nine companies have been accepted into Bayer's Digital Health Partnership Program, as annouced on the EU Start...

"We do not think femtech is niche": Interview with Pollie...
EU-Startups
·
Sep 21, 2021

Around 30% of women have a complex chronic condition like a hormone imbalance or autoimmune condition, and yet patient ex...

Why Time-Not Just Money-Needs To Be Part of the Conversat...
Well+Good
·
Aug 19, 2020

In an ideal world, digital media entrepreneur Amber Nash would love to go to therapy once a month. She'd also be thrilled...

FAQ

What must I do to receive my equity or cash in the event of the conversion of my Crowd SAFE?

What must I do to receive my equity or cash in the event of the conversion of my Crowd SAFE?

Suppose the Company converts the Crowd SAFE as a result of an equity financing. In that case, you must open a custodial account with the custodian and sign subscription documentation to receive the equity securities. The Company will notify you of the conversion trigger, and you must complete necessary documentation within 30 days of such notice. If you do not complete the required documentation with that time frame, you will only be able to receive an amount of cash equal to (or less in some circumstances) your investment amount. Unclaimed cash will be subject to relevant escheatment laws. For more information, see the Crowd SAFE for this offering.


If the conversion of the Crowd SAFE is triggered as a result of a Liquidity Event (e.g. M&A or an IPO), then you will be required to select between receiving a cash payment (equal to your investment amount or a lesser amount) or equity.  You are required to make your selection (and complete any relevant documentation) within 30 days of such receiving notice from the Company of the conversion trigger, otherwise you will receive the cash payment option, which will be subject to relevant escheatment laws. The equity consideration varies depending on whether the Liquidity Event occurs before or after an equity financing. For more information, see the Crowd SAFE for this offering.

How do I earn a return?

How do I earn a return?

We are using Republic's Crowd SAFE security. Learn how this translates into a return on investment here.

What are helpful parallels for Pollie's product?

What are helpful parallels for Pollie's product?

We like to say we are the female health equivalent of the Livongos and Omadas of the world: just like these players started with digitizing diabetes prevention programs and used that as a playbook for expanding into other chronic conditions, we are starting with PCOS and plan to expand into other hormone, autoimmune, and gut disorders that impact menstruating people. 

What is required to be diagnosed with PCOS?

What is required to be diagnosed with PCOS?

Common PCOS symptoms include irregular menstruation (often longer, 35+ days cycles), acne, hair loss, hirsutism, difficulty losing weight, mental health conditions, skin discoloration, fatigue, period pain, bad PMS symptoms, and more.

In order to be diagnosed with PCOS, someone must fulfill at least 2 of 3 of the Rotterdam criteria:

  1. Irregular or absent ovulation - Detected with patient-reported irregular menstrual cycles that do not fall in a "normal" 21 - 35 day window
  2. High levels of androgens (i.e., "male" hormones like testosterone and DHEA-S) - Detected with blood work
  3. Polycystic ovaries - Detected with an internal (transvaginal) ultrasound

PCOS can be catalyzed by a variety of factors, and it sits at the intersection of a hormonal, metabolic, inflammatory, and genetic condition. 70-90% of people with PCOS are insulin resistant which can catalyze or worsen symptoms, as can things like high stress levels and systemic inflammation due to autoimmune conditions or allergies.

Why does someone need Pollie if they already have a doctor?

Why does someone need Pollie if they already have a doctor?

The typical PCOS patient experience is cumbersome, to say the least. Despite PCOS being a serious chronic condition that sits at the intersection of many bodily systems, symptoms are still treated as discrete issues and there is a lot of bouncing around to different providers (e.g., OBGYN, PCP, endocrinologist, dermatologist). There are three main issues with this approach:

1. Our healthcare system does not allow physicians ample time to fully explain the implications of PCOS to their patients. Even if someone has geographic and financial access to receive care from one of the few PCOS centers in the US, there is still a gap when it comes to day-to-day support.

2. Physicians are not experts in nutrition nor behavior science! That is where Pollie's registered dietitians and health coaches come in.

3. Many physicians are not up-to-date on the latest PCOS research or best-in-class practices because of various systemic factors (e.g., medical school curriculum).


That is where Pollie comes in. Through combining behavior science with the latest PCOS research, our product helps people learn how to manage their PCOS not just in a personalized way, but a sustainable way that fits their goals, preference, and lifestyle.


You can learn more about the status quo PCOS patient experience, and why it's unacceptable, in this article.

What is the scope of Pollie's PCOS app?

What is the scope of Pollie's PCOS app?

Today, Pollie's scope falls within the realm of behavior change. The care teams who work with our members are made up of registered dietitians (RDs) and health coaches. Because we are not yet contracting with insurance and make recommendations (not prescriptions) to members, this allows us to work across state lines. This was a strategic decision given our early stage and decision to start with a target market of people who already know they have PCOS. We do plan to expand our scope in the future when the time is right. 

Is Pollie's app 100% virtual?

Is Pollie's app 100% virtual?

Pollie's subscription provides 100% virtual care so that members can easily chat with your care team and meet with PCOS specialists all from the comfort of your home. If a member decides to get labs drawn through us, we will send them to a nearby Quest facility for the blood draw.

Do new members need to get their labs drawn through Pollie?

Do new members need to get their labs drawn through Pollie?

Nope! We can also work with you if you would provide your physician order labs for insurance coverage, or use recently-drawn labwork. Labs are highly recommended for a more personalized experience. Roughly 50% of our members get labs drawn through Pollie.

Is Pollie covered by insurance and HSA / FSA plans?

Is Pollie covered by insurance and HSA / FSA plans?

The cost of Pollie's subscription is not currently covered by insurance. This is something we are actively working on! However, we are HSA / FSA reimbursable.

What is the research behind Pollie's approach?

What is the research behind Pollie's approach?

Research shows that the personalized, holistic recommendations found in Pollie's approach lead to improved PCOS health outcomes and improved patient wellbeing. You can learn more about the research behind our approach here.

What are the credentials of Pollie care teams?

What are the credentials of Pollie care teams?

Our care team includes health coaches and registered dietitians (RDs) who are specialized in female hormone conditions like PCOS and also have functional medicine training. Our care teams are also well-versed in mediums such as intuitive eating, gentle nutrition / exercise, and weight inclusivity / Health At Every Size (HAES) for members who have a history of disordered eating habits. All care protocols are research-backed and OBGYN-approved.

Still have questions? Check the discussion section.
Show all FAQ

Risks

We have a limited operating history upon which you can evaluate our performance, and accordingly, our prospects must be considered in light of the risks that any new company encounters.

The Company is still in an early phase and we are just beginning to implement our business plan. There can be no assurance that we will ever operate profitably. The likelihood of our success should be considered in light of the problems, expenses, difficulties, complications and delays usually encountered by early stage companies. The Company may not be successful in attaining the objectives necessary for it to overcome these risks and uncertainties.

Global crises and geopolitical events, including without limitation, COVID-19 can have a significant effect on our business operations and revenue projections.

The Company’s revenue was adversely affected related to the COVID-19 crisis. Another significant outbreak of contagious diseases, such as COVID-19, in the human population could result in a widespread health crisis. Additionally, geopolitical events, such as wars or conflicts, could result in global disruptions to supplies, political uncertainty and displacement. Each of these crises could adversely affect the economies and financial markets of many countries, including the United States where we principally operate, resulting in an economic downturn that could reduce the demand for our products and services and impair our business prospects, including as a result of being unable to raise additional capital on acceptable terms, if at all.

The amount of capital the Company is attempting to raise in this Offering may not be enough to sustain the Company’s current business plan.

In order to achieve the Company’s near and long-term goals, the Company may need to procure funds in addition to the amount raised in the Offering. There is no guarantee the Company will be able to raise such funds on acceptable terms or at all. If we are not able to raise sufficient capital in the future, we may not be able to execute our business plan, our continued operations will be in jeopardy and we may be forced to cease operations and sell or otherwise transfer all or substantially all of our remaining assets, which could cause an Investor to lose all or a portion of their investment.

We may face potential difficulties in obtaining capital.

We may have difficulty raising needed capital in the future as a result of, among other factors, our lack of revenues from sales, as well as the inherent business risks associated with our Company and present and future market conditions. Additionally, our future sources of revenue may not be sufficient to meet our future capital requirements. As such, we may require additional funds to execute our business strategy and conduct our operations. If adequate funds are unavailable, we may be required to delay, reduce the scope of or eliminate one or more of our research, development or commercialization programs, product launches or marketing efforts, any of which may materially harm our business, financial condition and results of operations.

We may not have enough authorized capital stock to issue shares of common stock to investors upon the conversion of any security convertible into shares of our common stock, including the Securities.

Unless we increase our authorized capital stock, we may not have enough authorized common stock to be able to obtain funding by issuing shares of our common stock or securities convertible into shares of our common stock. We may also not have enough authorized capital stock to issue shares of common stock to investors upon the conversion of any security convertible into shares of our common stock, including the Securities.

We may implement new lines of business or offer new products and services within existing lines of business.

As an early-stage company, we may implement new lines of business at any time. There are substantial risks and uncertainties associated with these efforts, particularly in instances where the markets are not fully developed. In developing and marketing new lines of business and/or new products and services, we may invest significant time and resources. Initial timetables for the introduction and development of new lines of business and/or new products or services may not be achieved, and price and profitability targets may not prove feasible. We may not be successful in introducing new products and services in response to industry trends or developments in technology, or those new products may not achieve market acceptance. As a result, we could lose business, be forced to price products and services on less advantageous terms to retain or attract clients or be subject to cost increases. As a result, our business, financial condition or results of operations may be adversely affected.

We rely on other companies to provide services for our products.

We depend on third party vendors to meet our contractual obligations to our customers and conduct our operations. Our ability to meet our obligations to our customers may be adversely affected if vendors do not provide the agreed-upon services in compliance with customer requirements and in a timely and cost-effective manner. Likewise, the quality of our services may be adversely impacted if companies to whom we delegate certain services do not perform to our, and our customers’, expectations. Our vendors may also be unable to quickly recover from natural disasters and other events beyond their control and may be subject to additional risks such as financial problems that limit their ability to conduct their operations. The risk of these adverse effects may be greater in circumstances where we rely on only one or two vendors for a particular service.

We rely on various intellectual property rights, including trademarks, in order to operate our business.

The Company relies on certain intellectual property rights to operate its business. The Company’s intellectual property rights may not be sufficiently broad or otherwise may not provide us a significant competitive advantage. In addition, the steps that we have taken to maintain and protect our intellectual property may not prevent it from being challenged, invalidated, circumvented or designed-around, particularly in countries where intellectual property rights are not highly developed or protected. In some circumstances, enforcement may not be available to us because an infringer has a dominant intellectual property position or for other business reasons, or countries may require compulsory licensing of our intellectual property. Our failure to obtain or maintain intellectual property rights that convey competitive advantage, adequately protect our intellectual property or detect or prevent circumvention or unauthorized use of such property, could adversely impact our competitive position and results of operations. We also rely on nondisclosure and noncompetition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary rights. There can be no assurance that these agreements will adequately protect our trade secrets and other proprietary rights and will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or other proprietary rights. As we expand our business, protecting our intellectual property will become increasingly important. The protective steps we have taken may be inadequate to deter our competitors from using our proprietary information. In order to protect or enforce our intellectual property rights, we may be required to initiate litigation against third parties, such as infringement lawsuits. Also, these third parties may assert claims against us with or without provocation. These lawsuits could be expensive, take significant time and could divert management’s attention from other business concerns. We cannot assure you that we will prevail in any of these potential suits or that the damages or other remedies awarded, if any, would be commercially valuable.

The Company’s success depends on the experience and skill of its executive officers and key personnel.

We are dependent on our executive officers and key personnel. These persons may not devote their full time and attention to the matters of the Company. The loss of all or any of our executive officers and key personnel could harm the Company’s business, financial condition, cash flow and results of operations.

Although dependent on certain key personnel, the Company does not have any key person life insurance policies on any such people.

We are dependent on certain key personnel in order to conduct our operations and execute our business plan, however, the Company has not purchased any insurance policies with respect to those individuals in the event of their death or disability. Therefore, if any of these personnel die or become disabled, the Company will not receive any compensation to assist with such person’s absence. The loss of such person could negatively affect the Company and our operations. We have no way to guarantee key personnel will stay with the Company, as many states do not enforce non-competition agreements, and therefore acquiring key man insurance will not ameliorate all of the risk of relying on key personnel.

In order for the Company to compete and grow, it must attract, recruit, retain and develop the necessary personnel who have the needed experience.

Recruiting and retaining highly qualified personnel is critical to our success. These demands may require us to hire additional personnel and will require our existing management and other personnel to develop additional expertise. We face intense competition for personnel, making recruitment time-consuming and expensive. The failure to attract and retain personnel or to develop such expertise could delay or halt the development and commercialization of our product candidates. If we experience difficulties in hiring and retaining personnel in key positions, we could suffer from delays in product development, loss of customers and sales and diversion of management resources, which could adversely affect operating results. Our consultants and advisors may be employed by third parties and may have commitments under consulting or advisory contracts with third parties that may limit their availability to us, which could further delay or disrupt our product development and growth plans.

We need to rapidly and successfully develop and introduce new products in a competitive, demanding and rapidly changing environment.

To succeed in our intensely competitive industry, we must continually improve, refresh and expand our product and service offerings to include newer features, functionality or solutions, and keep pace with changes in the industry. Shortened product life cycles due to changing customer demands and competitive pressures may impact the pace at which we must introduce new products or implement new functions or solutions. In addition, bringing new products or solutions to the market entails a costly and lengthy process, and requires us to accurately anticipate changing customer needs and trends. We must continue to respond to changing market demands and trends or our business operations may be adversely affected.

The development and commercialization of our products is highly competitive.

We face competition with respect to any products that we may seek to develop or commercialize in the future. Our competitors include major companies worldwide. Many of our competitors have significantly greater financial, technical and human resources than we have and superior expertise in research and development and marketing approved products and thus may be better equipped than us to develop and commercialize products. These competitors also compete with us in recruiting and retaining qualified personnel and acquiring technologies. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Accordingly, our competitors may commercialize products more rapidly or effectively than we are able to, which would adversely affect our competitive position, the likelihood that our products will achieve initial market acceptance, and our ability to generate meaningful additional revenues from our products.

Industry consolidation may result in increased competition, which could result in a loss of customers or a reduction in revenue.

Some of our competitors have made or may make acquisitions or may enter into partnerships or other strategic relationships to offer more comprehensive services than they individually had offered or achieve greater economies of scale. In addition, new entrants not currently considered to be competitors may enter our market through acquisitions, partnerships or strategic relationships. We expect these trends to continue as companies attempt to strengthen or maintain their market positions. The potential entrants may have competitive advantages over us, such as greater name recognition, longer operating histories, more varied services and larger marketing budgets, as well as greater financial, technical and other resources. The companies resulting from combinations or that expand or vertically integrate their business to include the market that we address may create more compelling service offerings and may offer greater pricing flexibility than we can or may engage in business practices that make it more difficult for us to compete effectively, including on the basis of price, sales and marketing programs, technology or service functionality. These pressures could result in a substantial loss of our customers or a reduction in our revenue.

If we are unsuccessful in adding users of our platform, or if our clients decrease their level of engagement, our revenue, financial results, and business may be significantly harmed.

We offer an online platform that helps women meet specialists who provide hormonal health solutions and enables women to achieve their personalized hormonal health goals with the support of specialists. The amount of users of our platform and our client’s level of engagement will be critical to our success. Our financial performance will be significantly determined by our success in adding, retaining, and engaging active users of our platform and the services offered. If clients do not perceive our platform or services provided thereunder to be useful, reliable, and trustworthy, we may not be able to attract or retain users or otherwise maintain or increase the frequency and duration of their engagement. There is no guarantee that we will not experience an erosion of our active client base or engagement levels in the future.

Damage to our reputation could negatively impact our business, financial condition and results of operations.

Our reputation and the quality of our brand are critical to our business and success in existing markets, and will be critical to our success as we enter new markets. Any incident that erodes consumer loyalty for our brand could significantly reduce its value and damage our business. We may be adversely affected by any negative publicity, regardless of its accuracy. Also, there has been a marked increase in the use of social media platforms and similar devices, including blogs, social media websites and other forms of internet-based communications that provide individuals with access to a broad audience of consumers and other interested persons. The availability of information on social media platforms is virtually immediate as is its impact. Information posted may be adverse to our interests or may be inaccurate, each of which may harm our performance, prospects or business. The harm may be immediate and may disseminate rapidly and broadly, without affording us an opportunity for redress or correction.

We have not prepared any audited financial statements.

The financial statements attached as Exhibit A to this Form C have been “reviewed” only and such financial statements have not been verified with outside evidence as to management’s amounts and disclosures. Additionally, tests on internal controls have not been conducted. Therefore, you will have no audited financial information regarding the Company’s capitalization or assets or liabilities on which to make your investment decision.

Our business could be negatively impacted by cyber security threats, attacks and other disruptions.

We may face advanced and persistent attacks on our information infrastructure where we manage and store various proprietary information and sensitive/confidential data relating to our operations. These attacks may include sophisticated malware (viruses, worms, and other malicious software programs) and phishing emails that attack our products or otherwise exploit any security vulnerabilities. These intrusions sometimes may be zero-day malware that are difficult to identify because they are not included in the signature set of commercially available antivirus scanning programs. Experienced computer programmers and hackers may be able to penetrate our network security and misappropriate or compromise our confidential information or that of our customers or other third-parties, create system disruptions, or cause shutdowns. Additionally, sophisticated software and applications that we produce or procure from third-parties may contain defects in design or manufacture, including “bugs” and other problems that could unexpectedly interfere with the operation of the information infrastructure. A disruption, infiltration or failure of our information infrastructure systems or any of our data centers as a result of software or hardware malfunctions, computer viruses, cyber-attacks, employee theft or misuse, power disruptions, natural disasters or accidents could cause breaches of data security, loss of critical data and performance delays, which in turn could adversely affect our business.

Security breaches of confidential customer information, in connection with our electronic processing of credit and debit card transactions, or confidential employee information may adversely affect our business.

Our business requires the collection, transmission and retention of personally identifiable information, in various information technology systems that we maintain and in those maintained by third parties with whom we contract to provide services. The integrity and protection of that data is critical to us. The information, security and privacy requirements imposed by governmental regulation are increasingly demanding. Our systems may not be able to satisfy these changing requirements and customer and employee expectations, or may require significant additional investments or time in order to do so. A breach in the security of our information technology systems or those of our service providers could lead to an interruption in the operation of our systems, resulting in operational inefficiencies and a loss of profits. Additionally, a significant theft, loss or misappropriation of, or access to, customers’ or other proprietary data or other breach of our information technology systems could result in fines, legal claims or proceedings.

The use of individually identifiable data by our business, our business associates and third parties is regulated at the state, federal and international levels.

The regulation of individual data is changing rapidly, and in unpredictable ways. A change in regulation could adversely affect our business, including causing our business model to no longer be viable. Costs associated with information security – such as investment in technology, the costs of compliance with consumer protection laws and costs resulting from consumer fraud – could cause our business and results of operations to suffer materially. Additionally, the success of our online operations depends upon the secure transmission of confidential information over public networks, including the use of cashless payments. The intentional or negligent actions of employees, business associates or third parties may undermine our security measures. As a result, unauthorized parties may obtain access to our data systems and misappropriate confidential data. There can be no assurance that advances in computer capabilities, new discoveries in the field of cryptography or other developments will prevent the compromise of our customer transaction processing capabilities and personal data. If any such compromise of our security or the security of information residing with our business associates or third parties were to occur, it could have a material adverse effect on our reputation, operating results and financial condition. Any compromise of our data security may materially increase the costs we incur to protect against such breaches and could subject us to additional legal risk.

The Company is not subject to Sarbanes-Oxley regulations and may lack the financial controls and procedures of public companies.

The Company may not have the internal control infrastructure that would meet the standards of a public company, including the requirements of the Sarbanes Oxley Act of 2002. As a privately-held (non-public) Company, the Company is currently not subject to the Sarbanes Oxley Act of 2002, and its financial and disclosure controls and procedures reflect its status as a development stage, non-public company. There can be no guarantee that there are no significant deficiencies or material weaknesses in the quality of the Company’s financial and disclosure controls and procedures. If it were necessary to implement such financial and disclosure controls and procedures, the cost to the Company of such compliance could be substantial and could have a material adverse effect on the Company’s results of operations.

Changes in federal, state or local laws and government regulation could adversely impact our business.

The Company is subject to legislation and regulation at the federal and local levels and, in some instances, at the state level. New laws and regulations may impose new and significant disclosure obligations and other operational, marketing and compliance-related obligations and requirements, which may lead to additional costs, risks of non-compliance, and diversion of our management's time and attention from strategic initiatives. Additionally, federal, state and local legislators or regulators may change current laws or regulations which could adversely impact our business. Further, court actions or regulatory proceedings could also change our rights and obligations under applicable federal, state and local laws, which cannot be predicted. Modifications to existing requirements or imposition of new requirements or limitations could have an adverse impact on our business.

We operate in a highly regulated environment, and if we are found to be in violation of any of the federal, state, or local laws or regulations applicable to us, our business could suffer.

We are also subject to a wide range of federal, state, and local laws and regulations. The violation of these or future requirements or laws and regulations could result in administrative, civil, or criminal sanctions against us, which may include fines, a cease and desist order against the subject operations or even revocation or suspension of our license to operate the subject business. As a result, we may incur capital and operating expenditures and other costs to comply with these requirements and laws and regulations.

Changes in employment laws or regulation could harm our performance.

Various federal and state labor laws govern our relationship with our employees and affect operating costs. These laws include minimum wage requirements, overtime pay, healthcare reform and the implementation of the Patient Protection and Affordable Care Act, unemployment tax rates, workers’ compensation rates, citizenship requirements, union membership and sales taxes. A number of factors could adversely affect our operating results, including additional government- imposed increases in minimum wages, overtime pay, paid leaves of absence and mandated health benefits, mandated training for employees, increased tax reporting and tax payment requirements for employees who receive tips, a reduction in the number of states that allow tips to be credited toward minimum wage requirements, changing regulations from the National Labor Relations Board and increased employee litigation including claims relating to the Fair Labor Standards Act.

State and federal securities laws are complex, and the Company could potentially be found to have not complied with all relevant state and federal securities law in prior offerings of securities.

The Company has conducted previous offerings of securities and may not have complied with all relevant state and federal securities laws. If a court or regulatory body with the required jurisdiction ever concluded that the Company may have violated state or federal securities laws, any such violation could result in the Company being required to offer rescission rights to investors in such offering. If such investors exercised their rescission rights, the Company would have to pay to such investors an amount of funds equal to the purchase price paid by such investors plus interest from the date of any such purchase. No assurances can be given the Company will, if it is required to offer such investors a rescission right, have sufficient funds to pay the prior investors the amounts required or that proceeds from this Offering would not be used to pay such amounts.

In addition, if the Company violated federal or state securities laws in connection with a prior offering and/or sale of its securities, federal or state regulators could bring an enforcement, regulatory and/or other legal action against the Company which, among other things, could result in the Company having to pay substantial fines and be prohibited from selling securities in the future.

The Company could potentially be found to have not complied with securities law in connection with this Offering related to a Reservation Campaign (also known as “Testing the Waters”).

Prior to filing this Form C, the Company engaged in a Reservation Campaign (also known as “testing the waters”) permitted under Regulation Crowdfunding (17 CFR 227.206), which allows issuers to communicate to determine whether there is interest in the offering. All communication sent is deemed to be an offer of securities for purposes of the antifraud provisions of federal securities laws. Any Investor who expressed interest prior to the date of this Offering should read this Form C thoroughly and rely only on the information provided herein and not on any statement made prior to the Offering. The communications sent to Investors prior to the Offering are attached as Exhibit D. Some of these communications may not have included proper disclaimers required for a Reservation Campaign.

The U.S. Securities and Exchange Commission does not pass upon the merits of the Securities or the terms of the Offering, nor does it pass upon the accuracy or completeness of any Offering document or literature.

You should not rely on the fact that our Form C is accessible through the U.S. Securities and Exchange Commission’s EDGAR filing system as an approval, endorsement or guarantee of compliance as it relates to this Offering. The U.S. Securities and Exchange Commission has not reviewed this Form C, nor any document or literature related to this Offering.

Neither the Offering nor the Securities have been registered under federal or state securities laws.

No governmental agency has reviewed or passed upon this Offering or the Securities. Neither the Offering nor the Securities have been registered under federal or state securities laws. Investors will not receive any of the benefits available in registered offerings, which may include access to quarterly and annual financial statements that have been audited by an independent accounting firm. Investors must therefore assess the adequacy of disclosure and the fairness of the terms of this Offering based on the information provided in this Form C and the accompanying exhibits.

The Company's management may have broad discretion in how the Company uses the net proceeds of the Offering.

Unless the Company has agreed to a specific use of the proceeds from the Offering, the Company’s management will have considerable discretion over the use of proceeds from the Offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

The Company has the right to limit individual Investor commitment amounts based on the Company’s determination of an Investor’s sophistication.

The Company may prevent any Investor from committing more than a certain amount in this Offering based on the Company’s determination of the Investor’s sophistication and ability to assume the risk of the investment. This means that your desired investment amount may be limited or lowered based solely on the Company’s determination and not in line with relevant investment limits set forth by the Regulation CF rules. This also means that other Investors may receive larger allocations of the Offering based solely on the Company’s determination.

The Company has the right to extend the Offering Deadline.

The Company may extend the Offering Deadline beyond what is currently stated herein. This means that your investment may continue to be held in escrow while the Company attempts to raise the Target Offering Amount even after the Offering Deadline stated herein is reached. While you have the right to cancel your investment in the event the Company extends the Offering Deadline, if you choose to reconfirm your investment, your investment will not be accruing interest during this time and will simply be held until such time as the new Offering Deadline is reached without the Company receiving the Target Offering Amount, at which time it will be returned to you without interest or deduction, or the Company receives the Target Offering Amount, at which time it will be released to the Company to be used as set forth herein. Upon or shortly after the release of such funds to the Company, the Securities will be issued and distributed to you.

The Company may also end the Offering early.

If the Target Offering Amount is met after 21 calendar days, but before the Offering Deadline, the Company can end the Offering by providing notice to Investors at least 5 business days prior to the end of the Offering. This means your failure to participate in the Offering in a timely manner, may prevent you from being able to invest in this Offering – it also means the Company may limit the amount of capital it can raise during the Offering by ending the Offering early.

The Company has the right to conduct multiple closings during the Offering.

If the Company meets certain terms and conditions, an intermediate close (also known as a rolling close) of the Offering can occur, which will allow the Company to draw down on seventy percent (70%) of Investor proceeds committed and captured in the Offering during the relevant period. The Company may choose to continue the Offering thereafter. Investors should be mindful that this means they can make multiple investment commitments in the Offering, which may be subject to different cancellation rights. For example, if an intermediate close occurs and later a material change occurs as the Offering continues, Investors whose investment commitments were previously closed upon will not have the right to re-confirm their investment as it will be deemed to have been completed prior to the material change.

Investors will not have voting rights, even upon conversion of the Securities and will grant a third-party nominee broad power and authority to act on their behalf.

In connection with investing in this Offering to purchase a Crowd SAFE (Simple Agreement for Future Equity) investors will designate Republic Investment Services LLC (f/k/a NextSeed Services, LLC) (the “Nominee”) to act on their behalf as agent and proxy in all respects. The Nominee will be entitled, among other things, to exercise any voting rights (if any) conferred upon the holder of the Securities or any securities acquired upon their conversion, to execute on behalf of an investor all transaction documents related to the transaction or other corporate event causing the conversion of the Securities, and as part of the conversion process the Nominee has the authority to open an account in the name of a qualified custodian, of the Nominee’s sole discretion, to take custody of any securities acquired upon conversion of the Securities. Thus, by participating in the Offering, investors will grant broad discretion to a third party (the Nominee and its agents) to take various actions on their behalf, and investors will essentially not be able to vote upon matters related to the governance and affairs of the Company nor take or effect actions that might otherwise be available to holders of the Securities and any securities acquired upon their conversion. Investors should not participate in the Offering unless he, she or it is willing to waive or assign certain rights that might otherwise be afforded to a holder of the Securities to the Nominee and grant broad authority to the Nominee to take certain actions on behalf of the investor, including changing title to the Security.

The Securities will not be freely tradable under the Securities Act until one year from the initial purchase date. Although the Securities may be tradable under federal securities law, state securities regulations may apply, and each Investor should consult with their attorney.

You should be aware of the long-term nature of this investment. There is not now and likely will not ever be a public market for the Securities. Because the Securities have not been registered under the Securities Act or under the securities laws of any state or foreign jurisdiction, the Securities have transfer restrictions and cannot be resold in the United States except pursuant to Rule 501 of Regulation CF. It is not currently contemplated that registration under the Securities Act or other securities laws will be effected. Limitations on the transfer of the Securities may also adversely affect the price that you might be able to obtain for the Securities in a private sale. Investors should be aware of the long-term nature of their investment in the Company. Each Investor in this Offering will be required to represent that they are purchasing the Securities for their own account, for investment purposes and not with a view to resale or distribution thereof. If a transfer, resale, assignment or distribution of the Security should occur prior to the conversion of the Security or after, if the Security is still held by the original purchaser directly, the transferee, purchaser, assignee or distribute, as relevant, will be required to sign a new Nominee Rider (as defined in the Security) and provide personally identifiable information to the Nominee sufficient to establish a custodial account at a later date and time. Under the Terms of the Securities, the Nominee has the right to place shares received from the conversion of the Security into a custodial relationship with a qualified third party and have said Nominee be listed as the holder of record. In this case, Investors will only have a beneficial interest in the equity securities derived from the Securities, not legal ownership, which may make their resale more difficult as it will require coordination with the custodian and Republic Investment Services.

Investors will not become equity holders until the Company decides to convert the Securities or until there is a change of control or sale of substantially all of the Company’s assets. The Investor may never directly hold equity in the Company.

Investors will not have an ownership claim to the Company or to any of its assets or revenues for an indefinite amount of time and depending on when and how the Securities are converted, the Investors may never become equity holders of the Company. Investors will not become equity holders of the Company unless the Company receives a future round of financing great enough to trigger a conversion and the Company elects to convert the Securities. The Company is under no obligation to convert the Securities. In certain instances, such as a sale of the Company or substantially all of its assets, an initial public offering or a dissolution or bankruptcy, the Investors may only have a right to receive cash, to the extent available, rather than equity in the Company. Further, the Investor may never become an equity holder, merely a beneficial owner of an equity interest, should the Company or the Nominee decide to move the Crowd SAFE or the securities issuable thereto into a custodial relationship.

Investors will not be entitled to any inspection or information rights other than those required by law.

Investors will not have the right to inspect the books and records of the Company or to receive financial or other information from the Company, other than as required by law. Other security holders of the Company may have such rights. Regulation CF requires only the provision of an annual report on Form C and no additional information. Additionally, there are numerous methods by which the Company can terminate annual report obligations, resulting in no information rights, contractual, statutory or otherwise, owed to Investors. This lack of information could put Investors at a disadvantage in general and with respect to other security holders, including certain security holders who have rights to periodic financial statements and updates from the Company such as quarterly unaudited financials, annual projections and budgets, and monthly progress reports, among other things.

Investors will be unable to declare the Security in “default” and demand repayment.

Unlike convertible notes and some other securities, the Securities do not have any “default” provisions upon which Investors will be able to demand repayment of their investment. The Company has ultimate discretion as to whether or not to convert the Securities upon a future equity financing and Investors have no right to demand such conversion. Only in limited circumstances, such as a liquidity event, may Investors demand payment and even then, such payments will be limited to the amount of cash available to the Company.

The Company may never elect to convert the Securities or undergo a liquidity event and Investors may have to hold the Securities indefinitely.

The Company may never conduct a future equity financing or elect to convert the Securities if such future equity financing does occur. In addition, the Company may never undergo a liquidity event such as a sale of the Company or an initial public offering. If neither the conversion of the Securities nor a liquidity event occurs, Investors could be left holding the Securities in perpetuity. The Securities have numerous transfer restrictions and will likely be highly illiquid, with no secondary market on which to sell them. If a transfer, resale, assignment or distribution of the Security should occur prior to the conversion of the Security or after, if the Security is still held by the original purchaser directly, the transferee, purchaser, assignee or distribute, as relevant, will be required to sign a new Nominee Rider (as defined in the Security) and provide personally identifiable information to the Nominee sufficient to establish a custodial account at a later date and time. Under the terms of the Securities, the Nominee has the right to place shares received from the conversion of the Security into a custodial relationship with a qualified third party and have said Nominee be listed as the holder of record. In this case, Investors will only have a beneficial interest in the equity securities derived from the Securities, not legal ownership, which may make their resale more difficult as it will require coordination with the custodian and Republic Investment Services. The Securities are not equity interests, have no ownership rights, have no rights to the Company’s assets or profits and have no voting rights or ability to direct the Company or its actions.

Any equity securities acquired upon conversion of the Securities may be significantly diluted as a consequence of subsequent equity financings.

The Company’s equity securities will be subject to dilution. The Company intends to issue additional equity to employees and third-party financing sources in amounts that are uncertain at this time, and as a consequence holders of equity securities resulting from the conversion of the Securities will be subject to dilution in an unpredictable amount. Such dilution may reduce the Investor’s control and economic interests in the Company.

The amount of additional financing needed by the Company will depend upon several contingencies not foreseen at the time of this Offering. Generally, additional financing (whether in the form of loans or the issuance of other securities) will be intended to provide the Company with enough capital to reach the next major corporate milestone. If the funds received in any additional financing are not sufficient to meet the Company’s needs, the Company may have to raise additional capital at a price unfavorable to their existing investors, including the holders of the Securities. The availability of capital is at least partially a function of capital market conditions that are beyond the control of the Company. There can be no assurance that the Company will be able to accurately predict the future capital requirements necessary for success or that additional funds will be available from any source. Failure to obtain financing on favorable terms could dilute or otherwise severely impair the value of the Securities.

In addition, the Company has certain equity grants and convertible securities outstanding. Should the Company enter into a financing that would trigger any conversion rights, the converting securities would further dilute the equity securities receivable by the holders of the Securities upon a qualifying financing.

Any equity securities issued upon conversion of the Securities may be substantially different from other equity securities offered or issued by the Company at the time of conversion.

In the event the Company decides to exercise the conversion right, the Company will convert the Securities into equity securities that are materially different from the equity securities being issued to new investors at the time of conversion in many ways, including, but not limited to, liquidation preferences, dividend rights, or anti-dilution protection. Additionally, any equity securities issued at the Conversion Price (as defined in the Crowd SAFE agreement) shall have only such preferences, rights, and protections in proportion to the Conversion Price and not in proportion to the price per share paid by new investors receiving the equity securities. Upon conversion of the Securities, the Company may not provide the holders of such Securities with the same rights, preferences, protections, and other benefits or privileges provided to other investors of the Company.

The forgoing paragraph is only a summary of a portion of the conversion feature of the Securities; it is not intended to be complete, and is qualified in its entirety by reference to the full text of the Crowd SAFE agreement, which is attached as Exhibit B.

There is no present market for the Securities and we have arbitrarily set the price.

The Offering price was not established in a competitive market. We have arbitrarily set the price of the Securities with reference to the general status of the securities market and other relevant factors. The Offering price for the Securities should not be considered an indication of the actual value of the Securities and is not based on our asset value, net worth, revenues or other established criteria of value. We cannot guarantee that the Securities can be resold at the Offering price or at any other price.

In the event of the dissolution or bankruptcy of the Company, Investors will not be treated as debt holders and therefore are unlikely to recover any proceeds.

In the event of the dissolution or bankruptcy of the Company, the holders of the Securities that have not been converted will be entitled to distributions as described in the Securities. This means that such holders will only receive distributions once all of the creditors and more senior security holders, including any holders of preferred stock, have been paid in full. No holders of any of the Securities can be guaranteed any proceeds in the event of the dissolution or bankruptcy of the Company.

While the Securities provide mechanisms whereby holders of the Securities would be entitled to a return of their subscription amount upon the occurrence of certain events, if the Company does not have sufficient cash on hand, this obligation may not be fulfilled.

Upon the occurrence of certain events, as provided in the Securities, holders of the Securities may be entitled to a return of the principal amount invested. Despite the contractual provisions in the Securities, this right cannot be guaranteed if the Company does not have sufficient liquid assets on hand. Therefore, potential Investors should not assume a guaranteed return of their investment amount.

There is no guarantee of a return on an Investor’s investment.

There is no assurance that an Investor will realize a return on their investment or that they will not lose their entire investment. For this reason, each Investor should read this Form C and all exhibits carefully and should consult with their attorney and business advisor prior to making any investment decision.

Show all Risks

Discussion

Ask questions and share feedback with the Pollie team below. If you have support related questions for Republic, please contact investors@republic.co.
Loading
Logo of Pollie

Pollie

Invest in Pollie
Republic

Giving everyone access to early-stage startup investing

For investors
  • Why invest
  • How it works
  • FAQ
  • Risks
  • Privacy policy
  • Accessibility
  • Cookie Preferences
  • Form CRS
For startups
  • Why raise
  • Learn
  • FAQ
  • Instruments
  • Crowd SAFE
  • Tokenized assets
Company
  • About
  • Journal
  • Events
  • Contact
  • We're hiring!
Dollar Refer a startup, get $2,500
Dollar Refer a startup, get $2,500

Invest in the app

Android app iOS app

Invest in the app

Android app iOS app

This site (the "Site") is owned and maintained by OpenDeal Inc., which is not a registered broker-dealer. OpenDeal Inc. does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities listed here are being offered by, and all information included on this Site is the responsibility of, the applicable issuer of such securities. The intermediary facilitating the offering will be identified in such offering’s documentation.

All related securities activity is conducted by OpenDeal Broker LLC a registered broker-dealer, Member of FINRA and SiPC, an affiliate of OpenDeal Inc. and OpenDeal Portal LLC, located at 149 5th Avenue, 10th Floor, New York, NY 10010. Please check our background on FINRA’s BrokerCheck.

Certain pages discussing the mechanics and providing educational materials regarding regulation crowdfunding offerings may refer to OpenDeal Broker LLC and OpenDeal Portal LLC collectively as “Republic”, solely for explanatory purposes.

Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC make investment recommendations and no communication, through this Site, or in any other medium, should be construed as a recommendation for any security offered on or off this investment platform. Investment opportunities posted on this Site are private placements of securities that are not publicly traded, involve a high degree of risk, may lose value including the total loss of invested capital, are subject to holding period requirements and are intended for investors who do not need a liquid investment. Past performance is not indicative of future results. Investors must be able to afford the loss of their entire investment. Only qualified investors, who understand the risks of early-stage investment and who meet the Republic's investment criteria may invest. Investors may be restricted to only Accredited Investors or non-U.S. persons, to invest in offerings hosted by OpenDeal Broker. Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC, nor any of their officers, directors, agents and employees make any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information on this Site or the use of information on this site. Offers to sell securities can only be made through official offering documents that contain important information about the investment and the issuers, including risks. Investors should carefully read the offering documents. Investors should conduct their own due diligence and are encouraged to consult with their tax, legal and financial advisors.

By accessing the Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy. Please also see OpenDeal Broker’s Business Continuity Plan and Additional Risk Disclosures. All issuers offering securities under regulation crowdfunding as hosted by OpenDeal Portal LLC are listed on the All Companies Page. The inclusion or exclusion of an issuer on the Platform Page and/or Republic’s Homepage, which includes offerings conducted under regulation crowdfunding as well as other exemptions from registration, is not based upon any endorsement or recommendation by OpenDeal Inc, OpenDeal Portal LLC, or OpenDeal Broker LLC, nor any of their affiliates, officers, directors, agents, and employees. Rather, issuers of securities may, in their sole discretion, opt-out of being listed on the Platform Page and Homepage.

Investors should verify any issuer information they consider important before making an investment.

Investments in private companies are particularly risky and may result in total loss of invested capital. Past performance of a security or a company does not guarantee future results or returns. Only investors who understand the risks of early stage investment and who meet the Republic's investment criteria may invest.

Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC verify information provided by companies on this Site and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Site can be found by searching the EDGAR database, or the offering documentation located on the Site when the offering does not require an EDGAR filing.

To help the government fight the funding of terrorism and money laundering activities, Federal law requires all financial institutions to obtain, verify, and record information that identifies each person who opens an account. Therefore, when you use the Services we will ask for your name, address, date of birth, and other information that will allow us to identify you. We may also ask to see your driver's license, passport or other identifying documents.

Republic and its affiliates are not and do not operate or act as a bank. Certain banking services are provided by BankProv, member FDIC / member DIF. FDIC coverage only applies in the event of bank failure. Digital (crypto) assets and investment products are not insured by the FDIC, may lose value, and are not deposits or other obligations of BankProv and are not guaranteed by BankProv. Terms and conditions apply.

Invest in startups using your credit card
You can invest using your credit card

Made in SF/NYC